At a glance

ClinicalIndex Comparison Record

N/ACompleted· 365 enrolled

Drug / intervention

Bevacizumab +1 moredrug

Likely dose

Bevacizumab 10 mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02627144

NCT02627144N/ACompleted

Compare CT.gov

AVASTIN® First Line in Metastatic Renal Cancer

Hoffmann-La Roche·observational·Posted Dec 10, 2015·Updated Aug 29, 2016

In Brief

An observational study evaluating Bevacizumab and Interferon alpha-2a for Renal Cell Cancer. Completed, enrolled 365 participants across 1 site.

Detailed Summary

This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsRenal Cell Cancer

CountriesGermany

Collaborators--

Timeline

N/ACompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJan 2008

Primary CompletionSep 2014

First PostedDec 2015

TodayJul 2026

First PostedDec 10, 2015

Enrollment StartJan 1, 2008

Primary CompletionSep 1, 2014

TodayJul 2, 2026

Enrollment to primary: 6.7 yearsPosted 10.6 years ago

Interventions

Bevacizumabdrug

Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.

Interferon alpha-2adrug

Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.